Huinno, an AI-driven cardiac monitoring startup, announced Monday that it has entered a strategic partnership with Yuhan USA Corporation to expand its presence in the US digital healthcare sector.
The collaboration will focus on sales channel development, localized marketing, and support for regulatory approval, logistics, and operations, aiming to accelerate Huinno’s entry into the US market.
At the core of the partnership is the deployment of Huinno’s AI-based electrocardiogram (ECG) monitoring solutions MEMO Patch M, MEMO Cue, and MEMO Care along with its clinical prediction platform, Vital-PICASO.
Read Also – Wave Life Sciences shares fall sharply after disappointing results from high-dose obesity drug
MEMO Patch M is a lightweight wearable ECG device capable of continuous monitoring for up to eight days, maintaining accurate readings even in high-risk clinical environments. MEMO Cue builds on this by analyzing inpatient ECG data in real time, enabling early detection of abnormalities and faster clinical decision-making. This system can be integrated into existing hospital infrastructure without additional network investments.
MEMO Care extends monitoring beyond hospital settings, leveraging AI to analyze up to 14 days of ECG data for home and outpatient care.
Separately, Vital-PICASO, developed by Huinno’s subsidiary Huinno AIM, analyzes patient vital signs to predict clinical deterioration, including hypotension, hypoxia, and cardiac arrest.
Through this partnership, Huinno aims to combine its advanced AI monitoring technologies with Yuhan USA’s local commercialization expertise, facilitating faster adoption within the US healthcare system.
“We aim to enhance patient safety and medical efficiency with solutions tailored to the US market, while strengthening our presence in the global digital health care sector,” Huinno CEO Gil Yeong-joon said.
